Artelo Biosciences (ARTL) Investor Presentation summary

Corporate highlights and strategy

• Advancing a platform of lipid signaling modulation drug candidates for pain, cancer, anxiety, and depression.

• Portfolio includes novel science, robust patent estate, and experienced leadership.

• Targeting billion-dollar markets with near-term clinical catalysts expected in the next 12–18 months.

Pipeline overview

• ART27.13: Dual cannabinoid receptor agonist for cancer-related anorexia and cachexia, in Phase 2.

• ART26.12: FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and various cancers, in Phase 1.

• ART12.11: CBD:TMP cocrystal for anxiety and depression, in late preclinical development.

ART27.13 clinical progress

• Addresses cancer anorexia cachexia syndrome (CACS), affecting up to 80% of advanced cancer patients with no FDA-approved treatment.

• Demonstrated dose-dependent weight gain and muscle preservation in preclinical and Phase 1 studies.

• CARES Phase 1/2 trials showed weight stabilization/gain and increased activity versus placebo.

• Well-tolerated safety profile up to 1300 μg/day, with most adverse events mild and transient.